Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
12 October 2021 - 10:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
using CRISPR/Cas9 technology both in vivo and ex
vivo, today announced the presentation of new data at the 29th
Annual Congress of the European Society of Gene & Cell Therapy
(ESGCT) meeting, taking place virtually from October 19-21, 2021.
“We are excited to share for the first time important
preclinical data and new developments highlighting both our
allogeneic T cell therapy platform as well as the utilization of
lipid nanoparticle-based delivery of the CRISPR/Cas9 gene editing
components to more efficiently engineer T cells for therapeutic
use,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino,
Ph.D. “Additionally, we will be presenting non-human primate data
from our in vivo platform where we have demonstrated our ability to
both insert a functional gene and inactivate a gene to treat AATD.
For AATD, a genetic disease that can cause lung dysfunction and/or
liver disease and which currently has no cure, our modular delivery
platform provides us the optionality for patient-tailored
treatments relevant to the disease manifestation. We look forward
to sharing these data with the scientific community as we continue
to advance our mission of delivering breakthrough genome editing
treatments for people with severe diseases.”
ESGCT Annual Congress Presentations
Oral Presentations:
Title: A Novel Strategy for Off-the-shelf T
Cell Therapies Evading Host T Cell and NK Cell
RejectionAbstract number:
OR18Date/Time: Wednesday, October 20, 2021, 10:45
a.m. CESTLocation: Session 2c: Immunotherapy for
cancer & CAR T cellsPresenting Author: Yong
Zhang, Ph.D., associate director, Cell Therapy
Title: Consecutive Genome Editing in Non-Human
Primate Achieves Durable Production of Human Alpha-1 Antitrypsin at
Physiologic Levels and Reduction of the Homologous Native
ProteinAbstract number:
OR12Date/Time: Wednesday, October 20, 2021, 10:15
a.m. CESTLocation: Session 2b: Gene editing
IPresenting Author: Sean Burns, M.D., vice
president of Intellia’s Disease Biology and Pharmacology group
Invited Talk:Title: Advances
in CRISPR/Cas9 Therapeutic Genome Editing for In Vivo and Ex Vivo
ApplicationsDate/Time: Friday, October 22, 2021,
11:30 a.m. CESTLocation: Session 7b: Liver and
metabolic diseases IIPresenting Author: Laura
Sepp-Lorenzino. Ph.D., chief scientific officer
Poster Presentation:Title:
Lipid Nanoparticles (LNPs) as a Superior CRISPR/Cas9 Delivery
Modality for Highly Efficient Multiplex Gene Editing of T Cells for
Adoptive Cell TherapyAbstract number:
P205Date/Time: Tuesday, October 19, 2021, 8:00
a.m. CESTPresenting Author: Aaron Prodeus, Ph.D.,
principal scientist, Cell Therapy
Additional data collected will be included in final meeting
presentations. All abstracts for the ESGCT Annual Congress will be
available on ESGCT’s website here.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
using CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the
therapy by using engineered human cells to treat cancer and
autoimmune diseases. Intellia’s deep scientific, technical and
clinical development experience, along with its robust intellectual
property portfolio, have enabled the company to take a leadership
role in harnessing the full potential of CRISPR/Cas9 to create new
classes of genetic medicine. Learn more at intelliatx.com.
Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited
to, express or implied statements regarding Intellia’s beliefs and
expectations regarding its: advancement and expansion of its
CRISPR/Cas9 technology to develop human therapeutic products, as
well as its ability to maintain and expand its related intellectual
property portfolio; expectations of the potential impact of the
coronavirus disease 2019 pandemic on strategy, future operations
and timing of its clinical trials or IND submissions; and
statements regarding the timing of regulatory filings regarding its
development programs.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; and the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies. For
a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is as of
the date of the release, and Intellia undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President, Investor Relations and
Corporate Communicationsian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Lisa QuTen Bridge
Communications+1-678-662-9166media@intelliatx.comlqu@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024